Semin intervent Radiol 2009; 26(1): 056-066
DOI: 10.1055/s-0029-1208384
© Thieme Medical Publishers

Endovascular Repair of Aortic Disease: A Venture Capital Perspective

Lucas W. Buchanan1 , S. William Stavropoulos2 , Joshua B. Resnick3 , Jeffrey Solomon2
  • 1Health Care Management Department, The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania
  • 2Department of Radiology, Division of Interventional Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
  • 3Department of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
Weitere Informationen


16. März 2009 (online)


Endovascular devices for the treatment of abdominal and thoracic aortic disease are poised to become the next $1 billion medical device market. A shift from open repair to endovascular repair, advances in technology, screening initiatives, and new indications are driving this growth. Although billion-dollar medical device markets are rare, this field is fraught with risk and uncertainty for startups and their venture capital investors. Technological hurdles, daunting clinical and regulatory timelines, market adoption issues, and entrenched competitors pose significant barriers to successful new venture creation. In fact, the number of aortic endografts that have failed to reach commercialization or have been pulled from the market exceeds the number of Food and Drug Administration–approved endografts in the United States. This article will shed some light on the venture capital mind-set and decision-making paradigm in the context of aortic disease.


Lucas W BuchananM.B.A. 

Health Care Management Department, The Wharton School, University of Pennsylvania

204 Colonial Penn Center, 3641 Locust Walk, Philadelphia, PA 19104-6218